Fundraising Fox
/Companies
Sign in

Acepodia

Founded 2016 · 61 employees on LinkedIn · 2 known investors

Find your way into Acepodia

Each arrow is one introduction. Sign up to fill in the first one.

103 people can intro you to Patrick

Ask Eric d'Esparbes to introduce you to Patrick Y. Yang

You →Eric · together at Antheia, Inc. →Patrick

Sign up to find every way you can get introduced to Acepodia

  • Your email: who you already know at Acepodia, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Acepodia team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Acepodia develops cell therapies for cancer treatment, leveraging proprietary immune cell engineering and tumor-targeting technology to create off-the-shelf therapeutic options for broad patient populations.

BiotechHealthtechMedical Devices

Founders & leadership

Acepodia was founded in 2016 by Patrick Y. Yang and Sonny Hsiao.

PYPatrick Y. Yang
Patrick Y. YangCo-founder, former EVP of Juno Therapeutics, Roche and GenentechPatrick Y. Yang is co-founder of Acepodia and formerly served as Executive Vice President at Juno Therapeutics, as well as holding roles at Roche and Genentech. He has expertise in biotech process research, development, manufacturing, and supply chain across operations in the U.S., Asia/Pacific, and Europe.
SH
Sonny HsiaoCo-founder, UC Berkeley cell biologist

Investors · 2

Also in the syndicate · 1

Digital Mobile Venturelead

Funding

SEC filings, press & company announcements

$209M disclosed across 2 of 3 rounds · 2021–2023

  • $100MSeries DJun 2023 · 2 sources

    Digital Mobile Venture (lead)

    Source ↗
  • $109MSeries CDec 2021 · 2 sources
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies - BioSpacebiospace.com · Dec 2021Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapiesglobenewswire.com · Dec 2021

Frequently asked questions

What does Acepodia do?
Acepodia develops cell therapies for cancer treatment, leveraging proprietary immune cell engineering and tumor-targeting technology to create off-the-shelf therapeutic options for broad patient populations.
Who founded Acepodia?
Acepodia was founded by Patrick Y. Yang, Sonny Hsiao in 2016.
Who are Acepodia's investors?
Acepodia's investors include Maxpro Ventures.
How much funding has Acepodia raised?
Acepodia has disclosed $209M raised across 2 of its 3 known rounds.